Takeda looks to further its investment in its European operations
Whilst the threat of Brexit is seeing a large number of companies moving their operations out of the UK and Europe altogether, Takeda is looking to place further investment. The pharmaceutical company are looking to build a new manufacturing facility in Ireland, providing over 40 jobs in Dublin.
Costing up to €100 million, the manufacturing facility will be over 32,000 sq ft and encompass two storeys. It will be situated next to an existing facility, located at Grange Castle Business Park. The manufacturing plant will be committed to the ongoing development of oncology drug Ninlaro.
"Ninlaro has the potential to help European patients with relapsed multiple myeloma by removing some of the barriers that can stand in the way of optimal treatment,” commented Takeda President Christophe Bianchi.
- Taiba Hospital: Patient care with promise
- Value of AI healthcare market set to soar to $22.79bn by 2023
- MEDNAX acquires radiology group Jefferson in latest industry swoop
“With Ninlaro, our hope is that many patients will be able to continue therapy until disease progression."
The news also is highly significant, given that another pharmaceutical giant, AstraZeneca has also placed investment in a new manufacturing plant in the UK for the development of prostate cancer drug Zoladex.
However, the company is also looking at further areas of future investment. Russia, for example, has become a hot contender, where Takeda will no doubt be looking at furthering their manufacturing capabilities through new and existing partnerships.